1990
A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference
1981
Influence of prognostic factors on survival in Ewing's sarcoma.
Glaubiger D, Makuch R, Schwarz J. Influence of prognostic factors on survival in Ewing's sarcoma. National Cancer Institute Monograph 1981, 285-8. PMID: 7300894.Peer-Reviewed Original ResearchConceptsPrimary diseaseEwing's sarcomaTreatment groupsSerum lactate dehydrogenase levelIntensive adjuvant chemotherapySystemic chemotherapy regimensLactate dehydrogenase levelsNumber of patientsSignificant differencesNational Cancer InstituteRecent treatment regimensAdjuvant chemotherapyChemotherapy regimensPrognostic factorsPrimary lesionTreatment regimensLDH levelsMetastatic statusSurvival resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer InstituteSarcomaPrimary site
1980
Influence of Histologic Subtype of Small Cell Carcinoma of the Lung on Clinical Presentation, Response to Therapy, and Survival2
Carney D, Matthews M, Ihde D, Bunn P, Cohen M, Makuch R, Gazdar A, Minna J. Influence of Histologic Subtype of Small Cell Carcinoma of the Lung on Clinical Presentation, Response to Therapy, and Survival2. Journal Of The National Cancer Institute 1980, 65: 1225-1230. PMID: 6253711, DOI: 10.1093/jnci/65.6.1225.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaHistologic subtypeCell carcinomaSame patientBiopsy tissueAggressive cytotoxic therapyChemotherapeutic response rateExtent of diseaseInitial performance statusIntermediate cell subtypeSignificant differencesPerformance statusCombination chemotherapyClinical presentationCytotoxic therapyTherapeutic decisionsPatientsLung cancer classificationResponse rateCell subtypesSubtypesTherapyCarcinomaLungWorking Party